Taysha Gene Therapies
Price & Volume
Stats
See more52W Range | $1.05-$5.50 |
Market Cap | $1B |
Shares Short | 41M |
Financials
See moreRevenue (12 Mos) | $6.3M |
Revenue Growth (YoY) | 78.6% |
Gross Profit (12 Mos) | $6.3M |
Diluted EPS | -$0.33 |
News
See moreYahoo Finance • 6 days ago
Taysha outlines accelerated BLA timeline for TSHA-102 with FDA Breakthrough Therapy designation and full global rights
Yahoo Finance • 24 days ago
Taysha Gene Therapies regains full rights to TSHA-102
Yahoo Finance • 25 days ago
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
Yahoo Finance • last month
Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory
About
CEO | Mr. Sean P. Nolan |
CFO | Mr. Kamran Alam CPA, M.B.A. |
Address | 3000 Pegasus Park Drive, Dallas, TX, United States, 75247 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 73 |
